Bolt Biotherapeutics Inc. is a clinical-stage immuno-oncology company. It engages in the discovery, development, and commercialization of pharmaceutical products. The company's principal product includes BDC-1001. Bolt Biotherapeutics Inc. is based in Redwood city, California.
| Revenue (Most Recent Fiscal Year) | $7.69M |
| Net Income (Most Recent Fiscal Year) | $-63.12M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 1.23 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.26 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -1741.26% |
| Net Margin (Trailing 12 Months) | -665.56% |
| Return on Equity (Trailing 12 Months) | -94.51% |
| Return on Assets (Trailing 12 Months) | -59.07% |
| Current Ratio (Most Recent Fiscal Quarter) | 3.13 |
| Quick Ratio (Most Recent Fiscal Quarter) | 3.13 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.48 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $1.22 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.29 |
| Earnings per Share (Most Recent Fiscal Year) | $-1.61 |
| Diluted Earnings per Share (Trailing 12 Months) | $-1.67 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 38.34M |
| Free Float | 36.00M |
| Market Capitalization | $12.04M |
| Average Volume (Last 20 Days) | 0.73M |
| Beta (Past 60 Months) | 0.96 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 6.10% |
| Percentage Held By Institutions (Latest 13F Reports) | 86.70% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |